PureTech Announces Leadership Transition
The Board of Directors has appointed Robert Lyne as Interim CEO with effect from today. Mr. Lyne joined PureTech as Chief Portfolio Officer in January 2024 and is an experienced leader of UK-listed life science innovation and venture capital companies, having previously served as CEO of Arix Bioscience plc. He will continue to work closely with PureTech's Board and management team as the Company delivers on its strategic objectives.
Sharon Barber-Lui, Interim Chair of PureTech's Board of Directors, said: 'The Board is grateful to Bharatt for his leadership and dedication to the Company over the past eight years. On behalf of the Board, I would like to sincerely thank him for his many contributions and wish him every success in the future. We remain focused on driving shareholder value, and Rob's extensive operational and capital markets experience will be key as he collaborates with the Board and engages with shareholders.'
Robert Lyne, Interim Chief Executive Officer of PureTech, said: 'I am honored to step into the role of Interim CEO and to continue working with this exceptional team at such an exciting time for the Company. PureTech has a high-value portfolio, and I look forward to building on the momentum we've generated as we advance our programs and deliver on meaningful milestones to create value for patients and shareholders.'
Dr. Bharatt Chowrira, said: 'It has been a true privilege to be part of PureTech's journey over the past eight years, including as CEO. I'm incredibly proud of what we've accomplished together—from advancing innovative science to progressing breakthrough clinical programs—and I leave with full confidence in the strength of the team and the exciting opportunities ahead for PureTech.'
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.
For more information, visit www.puretechhealth.com or connect with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
B Riley Financial Posts Q2 Profit Jump
Key Points Adjusted net revenue (non-GAAP) reached $51.5 million in Q2 2025, with investment banking and institutional brokerage making up most of the total. The company posted GAAP net income of $12.5 million in Q2 2025 and ended the quarter with no debt with $94.5 million in cash and securities as of June 30, 2025. A one-time dividend of $0.22 per share was declared, but no recurring dividend program was established. These 10 stocks could mint the next wave of millionaires › B. Riley Financial (NASDAQ:RILY), a diversified financial services firm operating across investment banking, wealth management, and asset disposition, released its earnings for the period ended June 30, 2025, on Aug. 7, 2025. The highlight was a debt-free balance sheet, $94.5 million in cash and securities as of June 30, 2025, and GAAP net income of $12.5 million. Adjusted net revenue (non-GAAP) was $51.5 million. There were no published analyst estimates or prior-period comparables for this stand-alone quarter after the carve-out of its securities operations, leaving direct performance comparisons unavailable. Overall, the period reflected stabilization in core businesses and improvements in profitability, but the sustainability of gains remains to be seen. B. Riley Financial's Business and Focus Areas B. Riley Financial operates a mix of capital markets, wealth management, and asset disposition businesses. Its core unit, B. Riley Securities, handles investment banking (which includes services like underwriting new stock or debt offerings and advising on mergers), institutional brokerage (stock and bond trading for clients), and research. Other segments include wealth management, auctions and liquidations, principal investments in communications, and a brands licensing business. The company's most recent focus is on strengthening its capital markets and core advisory practices. It aims to grow its footprint in high-growth sectors, particularly by raising capital for technology clients and expanding expertise in renewables and health care. Key success factors include team expansion and a disciplined approach to returning capital, as evidenced by its dividend announcements. Quarter in Review: Performance, Drivers, and Events The quarter's results spotlight the impact of a recent business carve-out, with B. Riley Securities reporting as the principal operating business for the first time. Adjusted net revenue, which excludes gains related to legacy investment positions, reached $51.5 million in Q2 2025. While institutional brokerage commissions contributed $25.4 million. Capital markets activity improved sequentially, as management noted, 'client activity increased significantly during the quarter, driving sequential improvements in both Institutional Brokerage commissions and Investment Banking revenue.' The company put a spotlight on capital markets products, including convertibles (debt that can become equity), variable rate financings, and continued growth in flexible funding solutions. Over the past year, the company has helped clients raise over $8 billion to support AI-driven investments, reflecting both client demand and the firm's advisory strengths. Additionally, B. Riley Securities added seven senior executives across key industry sectors, such as technology, health care, and real estate, aiming to enhance client service and drive new business. Hosting its 25th annual investor conference strengthened engagement, with several hundred institutional investors and companies attending. The period saw no reporting detail on other B. Riley Financial units such as wealth management, auctions and liquidations, or the brands portfolio. Past quarters showed asset sales and joint ventures, such as a 44 % retained stake in Great American Group, following majority sales and decomposing non-core segments. The company further reduced its exposure to legacy investment positions, as reflected by adjustments in its reported profit. No major product launches or significant new business lines outside capital markets were highlighted in this quarter. From a balance sheet perspective, the company ended with no outstanding debt and $94.5 million in cash and securities as of June 30, 2025, supporting a strong liquidity position. It declared a one-time $0.22 per share dividend, totaling $4.1 million, approved in Q2 2025. Management explicitly stated this was not intended as a recurring program. Looking Ahead: Guidance and Investor Considerations B. Riley Financial's management did not provide any quantitative financial guidance for the next quarter or for fiscal 2025. Instead, management characterized the current phase as one of stabilization and cautious optimism, indicating that improvement 'has continued into Q3 2025.' They also cautioned that the quarter's performance should not be annualized or taken as a reliable indicator for future periods, citing the lumpy nature of capital markets revenue and the effect of non-recurring gains. Investors will want to watch for greater reporting detail in future quarters as the operations of B. Riley Securities and legacy businesses mature post-carve-out. Key factors include sustained deal flow across capital markets, effectiveness of new personnel hires, the recurrence or decline of non-GAAP investment gains, and the approach to future capital returns. The shifting segment structure and changing client activity patterns will remain important variables for tracking the company's trajectory. The quarterly dividend was declared as a one-time event and does not reflect an ongoing policy. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,069%* — a market-crushing outperformance compared to 184% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
2 hours ago
- Globe and Mail
TPI Composites, Inc. Advances Chapter 11 Process with Court Approval of First-Day Motions
Secures Access to Liquidity and Financial Flexibility Operations Continue Uninterrupted for Employees, Customers, and Supply Partners Company Focused on Executing Strategic Initiatives for Long-Term Stability SCOTTSDALE, Ariz., Aug. 13, 2025 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (NASDAQ: TPIC) together with its domestic subsidiaries (collectively, 'TPI' or the 'Company') announced today that the U.S. Bankruptcy Court for the Southern District of Texas (the 'Bankruptcy Court') approved all first-day motions filed by the Company in connection with its voluntary chapter 11 proceedings. The approvals provide the Company with the operational flexibility and liquidity necessary to continue normal business operations during the chapter 11 process. Key motions approved include, interim approval for debtor-in-possession financing from its senior secured lenders of up to $82.5 million, the continuation of employee wages and benefits, maintenance of cash management systems, and the authority to pay certain prepetition obligations critical to ongoing operations. 'Our priority is to maintain stability and support for our employees, customers, and partners during this process,' said Bill Siwek, Chief Executive Officer of TPI. 'The court's approval of these first-day motions allows us to focus on executing our strategic initiatives to strengthen the Company for the long term.' Additional Information Additional information regarding the Company's court-supervised process is available at Court filings and other information related to the proceedings are available on a separate website administrated by the Company's claims agent, Kroll, at by calling Kroll representatives at (877) 280-2696 within the U.S. & Canada (or +1 (646) 290-7082 internationally for calls originating outside of the U.S.); or by sending an email to TPIinfo@ About TPI TPI Composites, Inc. is a global company focused on innovative and sustainable solutions to decarbonize and electrify the world. TPI delivers high-quality, costeffective composite solutions through long-term relationships with leading OEMs in the wind markets. TPI is headquartered in Scottsdale, Arizona and operates factories in the U.S., Mexico, Türkiye and India. TPI operates additional engineering development centers in Denmark and Germany and global service training centers in the U.S. and Spain. Forward-Looking Statements This release contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements, among other things, concerning: the adoption, implementation and consummation of a Chapter 11 plan of reorganization; the commencement of Chapter 11 proceedings in U.S. bankruptcy court; growth of the wind energy and electric vehicle markets and our addressable markets for our products and services; effects on our financial statements and our financial outlook; our business strategy, including anticipated trends and developments in and management plans for our business and the wind industry and other markets in which we operate; future financial results, operating results, revenues, gross margin, operating expenses, profitability, products, projected costs, warranties, our ability to improve our operating margins, and capital expenditures. These forward-looking statements are often characterized by the use of words such as 'estimate,' 'expect,' 'anticipate,' 'potential,' 'project,' 'plan,' 'intend,' 'seek,' 'believe,' 'forecast,' 'foresee,' 'likely,' 'may,' 'should,' 'goal,' 'target,' 'might,' 'will,' 'could,' 'predict,' 'continue' and the negative or plural of these words and other comparable terminology. Forward-looking statements are only predictions based on our current expectations and our projections about future events. You should not place undue reliance on these forward-looking statements. We undertake no obligation to update any of these forward-looking statements for any reason. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, the matters discussed in 'Risk Factors,' in our Annual Report on Form 10-K and other subsequent filings with the SEC.
Globe and Mail
2 hours ago
- Globe and Mail
BioSig Technologies Inc. Announces Pricing of $15 Million Public Offering
Los Angeles, CA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ('BioSig' or the 'Company'), which recently merged with Streamex Exchange Corporation ('Streamex') (NASDAQ: BSGM), today announced the pricing of its previously announced underwritten public offering of 3,852,149 shares of common stock at a public offering price of $3.90 per share. The offering is expected to close on or around August 15, 2025 subject to customary closing conditions. The gross proceeds from the offering, before deducting underwriter discounts and commissions and other estimated offering expenses are expected to be approximately $15,023,381.10. BioSig intends to use the net proceeds from the offering to purchase gold bullion in accordance with its investment policy, for working capital and for general corporate purposes. Clear Street and Needham & Company are acting as joint book-running managers of the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-276298) declared effective by the Securities and Exchange Commission (the 'SEC') on December 17, 2024. A final prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission, together with an accompanying base prospectus. The securities may be offered only by means of a written prospectus forming a part of the effective registration statement. Copies of the final prospectus supplement relating to the offering, together with the accompanying base prospectus, may be obtained, when available from the SEC's website at from Clear Street, Attention: Syndicate, 4 World Trade Center, 150 Greenwich St, Floor 46, New York, NY 10007, or by email at syndicate@ and Needham & Company, 250 Park Avenue, 10th Floor, New York, NY 10177, Attn: Prospectus Department, prospectus@ or by telephone at (800) 903-3268. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein. BioSig will not, and has been advised by the joint book-running managers that they and their affiliates will not, sell any of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Streamex Streamex is a RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and an institutional grade tokenization platform. Streamex is a wholly owned subsidiary of BioSig Technologies, Inc. About BioSig Technologies BioSig Technologies, Inc. is a medical device technology company with an advanced digital signal processing technology platform, the PURE EP™ Platform that delivers insights to electrophysiologists for ablation treatments of cardiovascular arrhythmias. The PURE EP™ Platform enables electrophysiologists to acquire raw signal data in real-time—absent of unnecessary noise or interference—to maximize procedural success and minimize unnecessary inefficiencies. As physician advocates, we believe that the ability to maintain the integrity of intracardiac signals with precision and clarity without driving up procedural costs has never been more pertinent. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the acquisition and recently announced convertible debenture financing and standby equity purchase agreement will be obtained, and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled "Risk Factors" in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.
